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The present format for kidney distribution begs 
for reform. as Halasz has said (1). What is in 
place now is a profound distortion of the so-called 
"Starzl point system" (2) which was based on three 
principles of which the most pervasive oper-
ationally was regional primacy: the two others were 
the right of the responsible physician to exercise 
medical judgement in any given case. and the right 
of the recipient to choose his/ her health care center 
and physician. Points toward selection as a recipi-
ent were given for time waiting. antigen matching, 
antibody analyses. medical urgency. and logistic 
practicality. 
The original point system (2) ensured that. with 
the exception of those organs with 6-antigen 
matches, the kidneys would be used for the popula-
tion from which they came (in other words locally). 
Lesser degrees of matching gave points, but be-
cause of the regional primacy a higher total 
matching score (short of perfect) did not catapult 
a kidney from its procurement area. The conse-
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quence was that waiting time was far more import-
ant and therefore more equitable than the 21 ';'" 
of potential points cited by Halasz. Rather than 
increasing the value of waiting to 31 % as Halasz 
believes. the revised rules of ] 989 which increased 
the credit for matching seriously eroded the value 
of waiting (3): we agree with him that the most 
recent change has all but eliminated credit for wait-
ing time. In addition. the rule changes of 1989 
imposed a bias against minority (particularly 
black) populations (3) that has become even more 
naked since then with the subsequent increased 
emphasis on HLA matching. We do not see merit 
in Halasz's proposal of adding other prejudicial 
factors: age, presensitization, previous transplan-
tation. or specific diseases. 
In fairness to Halasz. he concedes. at least in 
part, that he is recommending a restoration of the 
original point system. However. far from "failing 
to update the system" as Halasz has asserted. the 
problem has been over-modification. From the be-
ginning. the use of local and regional variances 
and more importantly the decisions taken by the 
UNOS Board of Directors have practically elimin-
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ated all factors except HLA matching, The original 
point system acknowledged tacitly that the HLA 
matching had inconsequential significance unless 
it was perfect: therefore it sharply restricted the 
use of matching beyond HLA identity. and gave 
modest but significant credit for presensitization 
which would be amplified to the extent that mis-
matching really was a factor in causing or perpetu-
ating sensitization (2), 
The increasing emphasis on tissue matching that 
wrecked the point system was the product of policy 
discussions at the UNOS Board of Directors and 
at lower levels of organization, These degenerated 
into debating and lobbying contests between the 
advocates of tissue matching (who for the most 
part were those managing or supplying the testing 
laboratories) and the transplant surgeons. who had 
realized for a long time that tissue matching did 
not accurately predict the outcome of kidney trans-
plantation (4-6) or for that matter the transplan-
tation of any other organ (7. S), Perhaps the re-
monstrances of transplant surgeons went unheeded 
because they lacked the passion generated by a 
direct vested interest. 
More likely. many could not understand why 
HLA. a genetically controlled and therefore pre-
sumably immutable biologic system. should not 
predict the outcome, Certainly. a correlation was 
expected by the senior author (TES) when in 
1964 he began with Terasaki the first prospective 
tissue matching trials in the world at the Univer-
sity of Colorado (9, 10). After 5 years of effort 
and analysis. no advantage could be demon-
strated except when there was a perfect match 
(11), This experience has been repeated and re-
ported hundreds of times. invariably followed by 
a riposte from a multicenter registry, to the be-
wilderment of those in the contributing programs 
who cannot in their individual experience identify 
the favorable trends from matching that are 
being claimed from the data pool to which they 
have sent their results. In the meanwhile, even 
proponents of matching have delivered hammer 
blows to its credibility, such as Terasaki's report 
at the 1992 Transplantation Society Congress 
that the use of one-haplotype matched (parent to 
offspring) kidney allografts gave no better results 
than those with kidneys from completely mis-
matched living non-relatives (12), This meant 
that the frequently cited difference in outcome 
between mismatched cadaver and parent to off-
spring transplantation (3-antigen matched) kid-
neys reflected primarily the preservation injury of 
the former versus the latter kidneys, When the 
physiologic quality of the mismatched unrelated 
organ was equivalent to that of the related kid-
ney, there was no matching advantage. 
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The most nagging intellectual concern to kidne~ 
transplant surgeons and others who wanted to, but 
could not. see an influence of HLA matchmg in 
their own practice was the knowledge that a perfect 
or near perfect match was universally conceded tll 
be a supreme determinant of success with honl' 
marrow transplantation (13. 14). It was hard t(1 
see why HLA matching was so critical in the hone 
marrow. but did not apply equally for whole organ 
transplantation field, Now. a plausible explanatloll 
for this dichotomy has been provided with the 
recent discovery that leukocytes migrate pef!-
operatively from transplanted whole organs to 
widely distributed recipient tissues where they can 
be identified many years later (15-18), 
The leukocytes leaving the graft are replaced hy 
recipient cells moving in the opposite direction, 
The events under immunosuppression leadmg 
eventually to the chimerism in the graft as well as 
ubiquitously in its recipient imply that there is 
a mutual engagement. activation. and ultimately 
clonal "silencing" of the immunocytes of both 
parties, The cell mixture can be seen as an ill \'/l'II 
two-way mixed lymphocyte reaction (MLR) ( Fig. 
I), Such a cell interaction cannot transpire after 
bone marrow transplantation because the con-
ditioning cytoablation of the recipient with ir-
radiation or myelotoxic drugs eliminates host hem-
atopoietic cells. Thus, the conditions in the bone 
marrow patient who can stimulate but not respond 
immunologically resemble a one-way MLR. 
The cells tha t persist long after the exchange 
between an organ allograft and the tissues of the 
recipient have the appearance of the dendritic 
leukocyte (antigen-presenting cells) shown by 
Steinman and Cohn (19, 20) to be of bone marro\\ 
origin, Although highly antigenic under normal 
conditions. these leukocytes appear to playa para-
doxical role in the "acceptance" of allo- and xeno-
grafts under immunosuppression and to participate 
in the first step of the induction of the donor-
specific non-reactivity that often has been noted in 
long surviving whole organ recipients (15-18). We 
have asked if the elusive "tolerance producing" 
veto and suppressor cells are the products of these 
interactions and further if they are altered dendritic 
cells (18) rather than changed T cells or other lin-
eages as usually has been assumed, 
In the delivery of the antigenic signal to the T 
cell, the dendritic cell (the most prominent chimeric 
cell in the patient tissues by morphologic criteria) 
is critical because it can modify the expression of 
cell interaction molecules, major histocompatibility 
complex (MHC) molecules, and adhesion mol-
ecules - all of which modify how antigen signals 
are heeded by T cells (20). The mechanism by . 
which mixed chimerism causes co-existing ceU 
populations to view each other in a progressively 
revised light is unknown. but that this occurs has 
been confirmed many times since it was first clearly 
described in bone marrow transplant models by 
Slavin and Strober (21) and even more clearly by 
Ildstad and Sachs (22). 
The ultimate non-reactivitv which mav or ma\ 
not require continued immu~osuppressi~n in th~D 
circumstances of whoh: organ transplantation 
(15-18) is not only of the recipient immunocytes 
in respect to the donor antigens. hut also the other 
way round as exemplified hy the rarity of graft 
versus host disease (GvHD) in cillmeric recipients 
of intestinal (23) and liver grafts (17) that contain 
a dense migratory leukocyte component. It is clear 
that the requisite seeding and intermingling of 
chimeric cells begin immediately after revascul-
arization (17). 
With each additional day under the protective 
umbrella of effective immunosuppression, a cor-
ollary expectation IS that the responsible donor-
recipient interactions. that are governed initially 
hy rules of histocompatibility, are influenced by 
a kind of "mutual natural immunosuppression". 
Here, each further level of incompatibility pro-
vokes countervailing increases in the variably can-
celling donor versus recipient and recipient versus 
donor cell reactivity. If the initial storm can be 
weathered, as has been increasingly possible with 
modern immunosuppression, the anticipated typ-
ing effect dwindles. 
In the aftermath, the number of peripheralized 
donor cells is small compared to the recipient 
leukocyte popUlation but the sustained effect may 
be large as has been suggested in another context 
by the apparent absorption of storage deposits in 
chimeric liver recipients with inborn errors of me-
tabolism caused by pan cellular enzyme deficiencies 
(24). The metabolic amelioration by presumed 
transmission of enzymes in these cases from a small 
normal cell population to a large abnormal one 
raises intriguing questions about a potential cell to 
cell effect of other molecules directly involved in 
immunologic processes including tolerance induc-
tion. 
It has been 27 years since the first prospective 
trials of HLA matching in kidney transplantation 
were begun (9) with the logical assumption that 
this kind of donor-recipient pairing would be a 
definitive way of improving the results. The power 
of expectation was so great that it has not been 
shaken in those doing the testing procedures in 
spite of the fact that thousands of conflicting 
reports have not settled the issue beyond a consen-
sus that there is an advantage with the uncommon 
perfect HLA match (25). Matching under all other 
circumstances has been thought by many to have 
HLA matching and the point system 
little or no merit and to have become an instrument 
of social injustice (3. 26). 
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